Universität zu Köln

Wilhelm, M., Smetak, M., Reimer, P., Geissinger, E., Ruediger, T., Metzner, B., Schmitz, N., Engert, A., Schaefer-Eckart, K. and Birkmann, J. (2016). First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation. Blood Cancer J., 6. LONDON: NATURE PUBLISHING GROUP. ISSN 2044-5385

Full text not available from this repository.

Abstract

Current guidelines recommend consolidation with autologous stem cell transplantation (autoSCT) after induction chemotherapy for most patients with peripheral T-cell lymphoma (PTCL). This assumption is based on five prospective phase II studies, three of which included <50 patients with limited follow-up. Here we present the final analysis of the prospective German study. The treatment regimen consisted of four to six cycles of CHOP chemotherapy followed by mobilizing therapy and stem cell collection. Patients in complete remission (CR) or partial remission (PR) underwent myeloablative chemo(radio) therapy and autoSCT. From January 2001 to July 2010, 111 patients were enrolled in the study. The main subgroups were PTCL not specified (n=42) and angioimmunoblastic T-cell lymphoma (n=37). Seventy-five (68%) of the 111 patients received transplantation. The main reason for not receiving autoSCT was progressive disease. In an intent-to-treat analysis, the complete response rate after myeloablative therapy was 59%. The estimated 5-year overall survival, disease-free survival and progression-free survival rates were 44%, 54% and 39%, respectively. The results of this study confirm that upfront autoSCT can result in long-term remissions in patients with all major subtypes of PTCL and therefore should be part of first-line therapy whenever possible.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Wilhelm, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Smetak, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Reimer, P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Geissinger, E. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ruediger, T. UNSPECIFIED UNSPECIFIED UNSPECIFIED Metzner, B. UNSPECIFIED UNSPECIFIED UNSPECIFIED Schmitz, N. UNSPECIFIED UNSPECIFIED UNSPECIFIED Engert, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Schaefer-Eckart, K. UNSPECIFIED UNSPECIFIED UNSPECIFIED Birkmann, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-270485
DOI:	10.1038/bcj.2016.63
Journal or Publication Title:	Blood Cancer J.
Volume:	6
Date:	2016
Publisher:	NATURE PUBLISHING GROUP
Place of Publication:	LONDON
ISSN:	2044-5385
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language NON-HODGKIN-LYMPHOMA; HIGH-DOSE CHEMOTHERAPY; PHASE-II; ALLOGENEIC TRANSPLANTATION; ROMIDEPSIN; PROGNOSIS; PATHOLOGY; REGIMEN; TREAT; FRONT Multiple languages Oncology; Hematology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/27048